Africa Injectable Drugs Market, by Molecule Type (Large Molecule and Small Molecule), by Route of Administration (Intravenous, Intramuscular, Sub-cutaneous, and Others, by End User (Hospitals, Specialty Clinics, and Others), and by Country/Region (South A

Africa Injectable Drugs Market, by Molecule Type (Large Molecule and Small Molecule), by Route of Administration (Intravenous, Intramuscular, Sub-cutaneous, and Others, by End User (Hospitals, Specialty Clinics, and Others), and by Country/Region (South Africa, Central Africa, and North Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Injectable drugs are injected by various routes of administration, such as intravenous, intramuscular, sub-cutaneous, etc. to treat a number of diseases such as cardiovascular, respiratory, cancer, etc. Healthcare professionals can inject many medications into different parts of the body. They will decide the most appropriate route of access depending on the situation.
Market Dynamics
Rapid therapeutic effect of injectable drugs is leads to increase the demand for the injectable products. Thus, key market players are engaged in enhancing manufacturing facilities of pharmaceutical products and strengthening their market position in Africa. This, in turn, is expected to drive the market growth. For instance, the African Union Commission (AUC) and the United Nations Industrial Development Organization (UNIDO) developed a business plan to accelerate the implementation of the Pharmaceutical Manufacturing Plan for Africa (PMPA), with funding from the German government. Moreover, injectable drugs offer potential benefits to patients with human immunodeficiency virus (HIV) on anti-retroviral therapy (ART) in low-income settings in sub-Saharan Africa. This in turn to increase usage of injectable drugs to treat HIV patients and thereby drive the growth of market in Africa. Furthermore, surge in presence of branded formulations is anticipated to drive the growth of market. For instance, branded formulations for bupivacaine injection such as Macaine HCL, (0.5% for spinal injection), Macaine HCL, (0.5% for injection with Dextrose), and Macaine HCL, (0.5% injection) are available in African countries, majorly in South Africa. Major manufacturers in Africa such as Pharma-Q Holdings (Pty) Ltd. and Adcock Ingram Limited offer bupivacaine injection in South Africa and other countries in Africa. In addition, manufactures operating in the market are appointing a distributors and thus increases the number of suppliers. This in turn to propel the growth of market. For instance, online distributors/pharmacies such as Seif Pharmacy in Egypt offers Isoptin (5 mg / 2ml) in the country. Pharmaceutical suppliers such as Pharmachemie (Pty) Ltd. and Sanofi-Aventis South Africa (Pty) Ltd. supply Fludarabine brands to the Department of Health, South Africa

Key features of the study:
This report provides an in-depth analysis of Africa injectable drugs market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in Africa injectable drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Apotex Inc., Fresenius Kabi India Pvt. Ltd., Hikma Pharmaceuticals PLC, Pfizer Inc., Bristol-Myers Squibb Company, Gland Pharma Limited, hameln pharma GmBH, Merck & Co., Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, and PANPHARMA S.A.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Africa injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing Africa injectable drugs market
Detailed Segmentation:
Africa Injectable Drugs Market, By Molecule Type:
Large Molecule
Small Molecule
Africa Injectable Drugs Market, By Route of Administration:
Intravenous
Intramuscular
Sub-cutaneous
Others
Africa Injectable Drugs Market, By End User:
Hospitals
Specialty Clinics
Others
Africa Injectable Drugs Market, By Country/Region:
North Africa
Molecule Type
Large Molecule
Small Molecule
Route of Administration
Intravenous
Intramuscular
Sub-cutaneous
Others
End User
Hospitals
Specialty Clinics
Others
Central Africa
Molecule Type
Large Molecule
Small Molecule
Route of Administration
Intravenous
Intramuscular
Sub-cutaneous
Others
End User
Hospitals
Specialty Clinics
Others
South Africa
Molecule Type
Large Molecule
Small Molecule
Route of Administration
Intravenous
Intramuscular
Sub-cutaneous
Others
End User
Hospitals
Specialty Clinics
Others
Company Profiles
Fresenius Kabi India Pvt. Ltd.
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Apotex Inc.
Hikma Pharmaceuticals PLC
Pfizer Inc.
Bristol-Myers Squibb Company
Gland Pharma Limited
hameln pharma gmbh
Merck & Co., Inc.
AbbVie Inc.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
PANPHARMA S.A.
“*” marked represents similar segmentation in other categories in the respective section.